Disseminated Primary Pulmonary Choriocarcinoma Successfully Treated by Chemotherapy: A Case Report and Literature Review

Kim, Jihye; Jae, Min; Kim, Mi-Kyung; Chung, Yun Jae; Lee, Eun Ju

doi:10.1080/07357907.2020.1804575

Cited by 7 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy including BEP (bleomycin, etoposide and cisplatin) and EMA-CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine) ( 15 , 32 ) is the commonly used therapeutic modality. Surgery or radiation in combination with chemotherapy was also employed for lung cancer with choriocarcinoma features of early stages ( 33 ).…”

Section: Discussionmentioning

confidence: 99%

Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

Li,

Hu,

Ning

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Accurate diagnoses are crucial in determining the most effective treatment across different cancers. In challenging cases, morphology-based traditional pathology methods have important limitations, while molecular profiling can provide valuable information to guide clinical decisions. We present a 35-year female with lung cancer with choriocarcinoma features. Her disease involved the right lower lung, brain, and thoracic lymph nodes. The pathology from brain metastasis was reported as “metastatic choriocarcinoma” (a germ cell tumor) by local pathologists. She initiated carboplatin and etoposide, a regimen for choriocarcinoma. Subsequently, her case was assessed by pathologists from an academic cancer center, who gave the diagnosis of “adenocarcinoma with aberrant expression of β-hCG” and finally pathologists at our hospital, who gave the diagnosis of “poorly differentiated carcinoma with choriocarcinoma features”. Genomic profiling detected a KRAS G13R mutation and transcriptomics profiling was suggestive of lung origin. The patient was treated with carboplatin/paclitaxel/ipilimumab/nivolumab followed by consolidation radiation therapy. She had no evidence of progression to date, 16 months after the initial presentation. The molecular profiling could facilitate diagnosing of challenging cancer cases. In addition, chemoimmunotherapy and local consolidation radiation therapy may provide promising therapeutic options for patients with lung cancer exhibiting choriocarcinoma features.

show abstract

Section: Discussionmentioning

confidence: 99%

Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

Li,

Hu,

Ning

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…However, the number and volume of multinucleated giant cells in giant cell carcinoma of the lung are lower than in PPC, and the level of β-hCG elevation is similarly lower. Furthermore, PPC must be differentiated from other types of pulmonary lesions ( 14 ). In this case, the patient exhibited a cough, sputum, fever, and other obvious symptoms, which are common manifestations of pulmonary infections, and this is why the patient was initially misdiagnosed with a pulmonary cyst complicated with infection.…”

Section: Discussionmentioning

confidence: 99%

The tumor or inflammation? a case report on primary pulmonary choriocarcinoma

Wang

Zhang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Choriocarcinoma is a rare malignant germ cell neoplasm with high invasiveness, the majority of which are pregnancy-related, and the female genital tract is the most prevalent site of the disease. Although early-stage choriocarcinoma typically metastasizes to the lungs, primary pulmonary choriocarcinoma is extremely rare. Primary pulmonary choriocarcinoma is difficult to diagnose, and it progresses rapidly. Combined with the difficulty of treatment, the prognosis of patients is generally poor. In this article, we retrospectively analyzed a case of female primary pulmonary choriocarcinoma, combined with a review of literature, to understand and describe the diagnostic and treatment progress of PPC.

show abstract

“…Although, a different study by Sato et al showed a lower complete response to EMACO (78−79.7%) [10]. It is also known that MEA chemotherapy (without Cyclophosphamide and Vincristine) is also effective, with a 74.4% of remission rate and 20.5% of resistance cases [11].…”

Section: Discussionmentioning

confidence: 99%

Risk Factors That Correlate with Resistance to First-Line Chemotherapy on High-risk Gestational Trophoblastic Neoplasia

Kurniadi

Zulvayanti²,

Suardi³

et al. 2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Gestational trophoblastic neoplasia (GTN) is a condition arising from abnormal proliferation of the trophoblastic cells. GTN incidence in Indonesia, precisely in Hasan Sadikin General Hospital, as many as 730 cases are reported per year. GTN is generally highly sensitive to chemotherapy, and multiagent chemotherapy regimens are recommended for high-risk GTN. Multiagent chemotherapy regimens for GTN treatment at Hasan Sadikin General Hospital are EMCO, with no other literature study describing chemotherapy resistance with EMCO today. AIM: This study aimed to identify risk factors associated with first-line chemotherapy resistance at Hasan Sadikin General Hospital. METHODS: In this cross-sectional study, medical records of 81 patients with high-risk GTN presented in the period from January 2018 to June 2021 who received EMCO chemotherapy at Hasan Sadikin General Hospital were retrieved from the archives, and medical data were reviewed and analyzed. Bivariate analysis was performed using the Chi-square test with Fisher’s exact alternative, and multivariate analysis using the binary logistic regression test. p < 0.05 was considered statistically significant. RESULTS: From 81 samples that received EMCO chemotherapy, 15 (18.5%) cases were resistant to EMCO, and 66 (81.5%) cases were responsive to EMCO. The risk factors associated with EMCO resistance were histopathological features and appropriate with EMCO chemotherapy interval (p < 0.05). Variables of age, previous pregnancy, GTN stage, FIGO prognostic score, stage, beta-hCG level, and side effects of EMCO did not significantly correlate with resistance to EMCO (p > 0.05). CONCLUSION: Histopathological features and appropriate chemotherapy intervals were associated with the incidence of resistance to EMCO in Hasan Sadikin General Hospital.

show abstract

Disseminated Primary Pulmonary Choriocarcinoma Successfully Treated by Chemotherapy: A Case Report and Literature Review

Cited by 7 publications

References 38 publications

Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

The tumor or inflammation? a case report on primary pulmonary choriocarcinoma

Risk Factors That Correlate with Resistance to First-Line Chemotherapy on High-risk Gestational Trophoblastic Neoplasia

Contact Info

Product

Resources

About